S-1/A: CapsoVision Files for IPO, Targeting $27.5 Million to Advance AI-Powered GI Endoscopy Solutions Amidst Continued Losses

CapsoVision, Inc., a medical technology company specializing in capsule endoscopy, is launching an initial public offering of 5,250,000 shares at an anticipated price range of $5.00 to $5.50 per share, aiming to raise approximately $22.83 million in net proceeds to fund R&D and general corporate purposes, despite a history of net losses and substantial doubt about its ability to continue as a going concern.

Summary

• CapsoVision, Inc. is a commercial-stage medical technology company developing advanced imaging and AI technologies for capsule endoscopy solutions to identify GI tract abnormalities.
• The company is offering 5,250,000 shares of common stock in its initial public offering, with an anticipated price range of $5.00 to $5.50 per share.
• Net proceeds from the offering are estimated to be approximately $22.83 million, or $26.67 million if the over-allotment option is fully exercised.
• Proceeds will be used for approximately $8 million in research and development activities (CapsoCam Plus AI, CapsoCam Colon, esophageal varices, pancreatic neoplasia studies), repayment of a $1 million loan, and the remainder for general corporate purposes.
• The company's primary product, CapsoCam Plus (small bowel capsule), has been used in over 135,000 patients worldwide as of March 31, 2025.
• Revenue for the year ended December 31, 2024, was approximately $11.8 million, a 21% increase from $9.8 million in 2023.
• Revenue for the three months ended March 31, 2025, was approximately $2.8 million, a 12% increase from $2.5 million in the same period of 2024.
• The primary driver for revenue growth was an increase in CapsoCam Plus capsules sold: 19% from 2023 to 2024, and 11% from Q1 2024 to Q1 2025.
• International sales accounted for 23% of total revenue in 2024 and Q1 2025, with France, Germany, and Canada being the largest international markets.
• The company reported net losses of $11.3 million in 2023, $19.9 million in 2024, and $5.4 million for the three months ended March 31, 2025.
• As of March 31, 2025, the accumulated deficit was $135.7 million, and cash was approximately $4.4 million.
• The 2024 audited financial statements include a footnote raising substantial doubt about the company's ability to continue as a going concern.
• CapsoVision is developing CapsoCam Colon for colon visualization and polyp detection/measurement, targeting FDA 510(k) clearance for the first generation in Q1 2026 and the second generation by end of Q2 2026.
• CapsoCam Colon incorporates self-developed AI for automated polyp detection and 3D-sensing technology for polyp size measurement.
• The company submitted its 510(k) for the first generation CapsoCam Colon to the FDA on June 10, 2025, and it has been accepted for review.
• CapsoVision received FDA 510(k) clearance in December 2024 for CapsoCam Plus for pediatric use (ages 2+) and telemedicine supervision (remote ingestion).
• The global small bowel capsule endoscopy market is estimated at $227 million in 2025, projected to reach $335 million by 2030.
• The global colon capsule endoscopy market is estimated at $213 million in 2025, projected to reach $311 million by 2030.
• The company has over 140 issued patents worldwide covering various aspects of its capsule and technology.
• Two material weaknesses in internal control over financial reporting were identified: insufficient controls over IT general controls/complementary user entity controls for applications, and lack of segregation of duties in financial reporting.
• The company plans to address these weaknesses by hiring a Corporate Controller and evaluating an ERP system upgrade/replacement.

Sentiment

Score: 4

Explanation: The company shows promising technological advancements and revenue growth, but its significant accumulated losses, negative cash flow, and explicit 'going concern' warning, coupled with reliance on future regulatory approvals and capital raises, indicate a high level of financial risk and uncertainty.

Positives

• Revenue has consistently increased year-over-year since U.S. direct sales began in 2020, with 21% growth in 2024 and 12% in Q1 2025.
• CapsoCam Plus has been used in over 135,000 patients worldwide, demonstrating market adoption.
• The company boasts a high customer retention rate of approximately 90% for 2024.
• CapsoCam Plus is the sole capsule endoscope on the market with a 360-degree panoramic view, offering superior diagnostic yield compared to competitors.
• The CapsoCam system is wire-free and zero-capex for providers, storing video onboard and eliminating patient-worn data recorders.
• Recent FDA 510(k) clearance for telemedicine supervision and pediatric use (ages 2+) for CapsoCam Plus expands market reach and convenience.
• CapsoCloud, the cloud-based platform, enables flexible, remote data analysis and management for clinicians.
• The upcoming CapsoCam Colon incorporates self-developed AI for automated polyp detection and a proprietary 3D-sensing technology for accurate polyp size measurement, capabilities competitive systems lack.
• The company has an experienced leadership team with deep industry expertise.
• A large intellectual property portfolio with over 140 issued patents provides a competitive advantage.
• Long-standing relationships (10-16+ years) with single-source suppliers in Asia (Largan, Toshiba, Moai/Speedbridge) for critical components.

Negatives

• The company has a history of net losses since inception, incurring $11.3 million in 2023, $19.9 million in 2024, and $5.4 million in Q1 2025.
• An accumulated deficit of $135.7 million as of March 31, 2025, indicates significant historical losses.
• The 2024 audited financial statements include a footnote raising substantial doubt about the company's ability to continue as a going concern.
• All current revenue is from CapsoCam Plus small bowel sales, making the company reliant on a single product in the near-term.
• CapsoCam Colon-related revenues are not expected until the second half of 2026, subject to timely FDA clearance.
• The company faces substantial geopolitical and trade risks due to reliance on single-source suppliers in Taiwan and Japan.
• Broad adoption of CapsoCam Colon depends on expanding beyond initial indicated patient populations and increasing accuracy, which may not succeed.
• Potential delays in obtaining FDA 510(k) clearance for CapsoCam Colon and AI-assisted reading technology for CapsoCam Plus could adversely impact commercialization.
• The effectiveness of CapsoCam capsules relies on patient adherence to preparation protocols and manual capsule retrieval, which can lead to missed screenings or lost data.
• The company operates in a highly competitive industry with established players like Medtronic, who have greater resources and market presence.
• Cost-containment efforts by customers and group purchasing organizations (GPOs) could lead to price concessions and impact profit margins.
• Identified two material weaknesses in internal control over financial reporting, which could affect financial reporting accuracy and timeliness.
• The company does not intend to pay dividends in the foreseeable future, meaning investor returns depend solely on stock price appreciation.

Risks

• History of net losses and expectation of additional losses in the foreseeable future.
• Substantial doubt about the ability to continue as a going concern, requiring additional financing.
• Reliance on CapsoCam Plus small bowel sales for all current and near-term revenue, with growth subject to competitive execution.
• Delayed CapsoCam Colon-related revenues until second half of 2026 due to anticipated FDA clearance timing.
• Broad adoption of CapsoCam Colon depends on expanding indicated patient populations, increasing accuracy, and achieving satisfactory completion rates.
• Longer-term efforts to expand GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies may not succeed.
• Potential delays or failure to obtain 510(k) clearance for initial or second-generation CapsoCam Colon, impacting commercialization.
• Regulatory challenges and delays in obtaining 510(k) clearance for CapsoCam capsules incorporating self-developed AI technology.
• Any failure or defect in the GI-tract capsule endoscopy solution could harm reputation, expose to liability, and reduce sales.
• Reliance on single-source suppliers in Asia (Taiwan and Japan) for critical components, posing supply chain disruption risks.
• Substantial geopolitical and trade risks (e.g., trade war, tariffs, supply chain interruptions) and natural disaster risks associated with Asia operations.
• Inadequate Medicare and other third-party payor reimbursement rates could hinder product commercialization.
• Failure to comply with regulatory requirements by the company or its distributors could lead to stringent penalties.
• Inability to obtain, maintain, enforce, and protect intellectual property rights could harm competitive position.
• Failure to identify patentable inventions or adequately protect patent rights could adversely affect commercial value.
• Risks associated with the use and development of artificial intelligence, including accuracy, clinician reliance, and evolving regulatory landscape.
• Actual or perceived failures to comply with data privacy and security laws (e.g., HIPAA, GDPR) could adversely affect business.
• Highly competitive industry with established players and aggressive pricing from Asia-based competitors.
• Cost-containment efforts of customers and group purchasing organizations could adversely affect sales and results.
• Effectiveness of CapsoCam capsules relies on patient adherence to protocols and manual retrieval, leading to potential missed diagnoses or lost data.
• Risks associated with CapsoCam capsule use, including retention, component failures, and aspiration.
• Need for additional capital to support business growth, which may not be available on favorable terms or may dilute existing stockholders.
• Challenges in leveraging existing sales channels to sell additional products and features.
• Adverse developments affecting the financial services industry could impact business operations.
• Changes to U.S. tariff measures and international trade relations could increase costs and affect demand.
• Complicated compliance requirements for cloud-based CapsoCloud platform, especially internationally and for government customers.
• Dependence on Aureliance, an authorized agent and importer in the EU/EEA, for a significant portion of international revenue.
• Limitations on the ability to utilize net operating loss carryforwards and research and development tax credits.
• Relationships with board-certified physicians are subject to various state laws, with no assurance of continued compliance.
• Risk of product recalls or production termination if manufacturing does not comply with regulations.
• Potential exposure to risks under federal and state laws prohibiting kickbacks and false or fraudulent claims.
• Failure to comply with the Foreign Corrupt Practices Act, economic and trade sanctions, and similar laws.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies could disrupt operations and lead to losses.
• Identified material weaknesses in internal control over financial reporting could affect financial reporting accuracy and timeliness.
• Potential litigation and other risks resulting from material weaknesses in internal control over financial reporting.
• Market price volatility of common stock due to various factors, including operating performance, industry reports, and economic conditions.
• Investors may experience immediate and substantial dilution from the IPO.
• Sales of a substantial number of shares by existing stockholders after lock-up periods could cause stock price to fall.
• Provisions in charter documents and Delaware law could discourage takeovers and lead to management entrenchment.
• Claims for indemnification by directors, officers, and agents may reduce available funds.
• Exclusive forum provision in the certificate of incorporation could limit stockholders' ability to bring claims.

Future Outlook

CapsoVision aims to expand its GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies to new medical indications like esophageal varices and pancreatic cancer, with feasibility studies planned for H2 2025 and H1 2026, respectively. The company plans to continue investing in AI to improve pathology detection accuracy and streamline diagnostic processes. Commercialization of CapsoCam Colon is targeted for H2 2026 in the U.S. and early 2027 in the EU, following anticipated FDA and CE Mark clearances. The company expects to continue incurring losses and negative cash flows in the foreseeable future as it scales its business and invests in R&D.

Management Comments

• "Our long-term, lifesaving vision is an ingestible capsule that, in a single convenient non-invasive procedure, screens for multiple cancers—esophageal, gastric, pancreatic, small-bowel, and colorectal—at early and precancerous stages, utilizing AI to analyze thousands of images captured in the GI tract."
• "We are building towards this goal with a planned succession of FDA-cleared indications, targeting existing and nascent markets."
• "We believe our CapsoCam Colon, once FDA cleared and commercialized, will be a superior capsule endoscopy system that will expand the market for colon capsule endoscopy."
• "We believe that our CapsoCams panoramic imaging is particularly well suited to visualizing the esophagus and measuring the size of varices, which may translate to significant improvement in sensitivity and staging accuracy."
• "Our in-house AI development team of experts who will leverage archived patient data on CapsoCloud as it grows during commercial use of CapsoCam Colon to make ongoing improvements to the AI algorithm."

Industry Context

CapsoVision operates in the highly competitive medical device market, specifically in diagnostic imaging and endoscopic procedures. The company's CapsoCam Plus competes with traditional enteroscopy and other capsule endoscopy systems from companies like Medtronic, IntroMedic, JinShan, and Ankon. For colon endoscopy, it faces competition from optical colonoscopy, flexible sigmoidoscopy, CT colonography, and stool-based DNA tests like Cologuard, as well as other capsule systems like Medtronic's PillCam COLON 2. The industry is characterized by rapid technological advancements, continuous product introductions, and increasing cost-containment pressures from third-party payors. CapsoVision aims to differentiate itself through its unique 360-degree panoramic view, wire-free data collection, AI-assisted reading, and 3D-sensing technology, positioning itself as a superior, non-invasive alternative in a market with significant unmet screening needs, particularly for colorectal and other GI cancers.

Comparison to Industry Standards

• CapsoCam Plus is the sole capsule endoscope with a 360-degree panoramic view available in the market, which is stated to provide a complete view of the GI mucosa unobstructed by folds and with complete coverage of the bending intestines inner curvature, resulting in demonstrated superior diagnostic yield compared to competitive end-view systems (e.g., Medtronic PillCam SB3).
• A 2024 retrospective study at a Japanese center showed CapsoCam Plus detected the duodenal papilla (Ampulla of Vater) at a significantly higher rate (82%) compared to Medtronic PillCam SB3 (15%, p < 0.001).
• An Austrian single-center study (2012-2018) comparing CapsoCam Plus, Medtronic PillCam, and IntroMedic MiroCam procedures observed an 82% detection rate for the duodenal papilla for CapsoCam Plus versus an average of 10% for PillCam and MiroCam.
• CapsoCam's wire-free data collection and remote data analysis via CapsoCloud are presented as zero-capex and more flexible solutions compared to competitors' systems (e.g., Medtronic's) that require patient-worn data recorders and equipment recovery/maintenance.
• CapsoCam Colon (subject to FDA clearance) incorporates deep learning AI for automated polyp detection and a proprietary 3D-sensing technology for polyp size measurement, capabilities that competitive systems like Medtronic PillCam COLON 2 (introduced in 2014) and AnX Robotics NaviCam ProScan (AI for small bowel, introduced in 2023) currently lack.
• For colon capsule endoscopy, CapsoCam Colon's successful completion rate is supported by a physical design encouraging timely transit and a battery lifetime currently twice that of competitors.
• Compared to CT colonography (CTC) following incomplete colonoscopy, colon capsule endoscopy has demonstrated a 61.5% higher diagnostic yield for polyps greater than 5mm and 3 times greater for all polyps (citing a systematic review with meta-analysis by Deding et al., 2020).
• In a multicenter prospective study, for average-risk screening patients, the sensitivity for polyps >= 6mm for colon capsule endoscopy was 78.2% compared to only 26.8% for CTC (TOPAZ study, Cash et al., 2021).
• Stool tests and blood tests (e.g., Cologuard, FIT, FOBT) have good sensitivity for cancer but under 50% for advanced precancerous lesions, and multi-targeted stool DNA tests like Cologuard have relatively high false-positive rates leading to unnecessary colonoscopies (75% of Cologuard-positive cases did not detect advanced neoplasia by colonoscopy in one study). CapsoVision believes its CapsoCam Colon will be superior in this context.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any litigation the outcome of which, if determined adversely, would materially and adversely affect its business, financial condition, or results of operations.
• The company may be involved in various legal proceedings from the normal course of business activities, such as intellectual property infringement, contract disputes, or employment matters.
• The company is not currently aware of any indemnification claims.

Related Party Transactions

• Since January 1, 2022, the company issued and sold 9,946,143 shares of Series H preferred stock to investors, including Eliyahou Harari (2,428,425 shares for $11,725,649.18) and Ching-Hang Shen (3,903,099 shares for $18,846,112.43), who are beneficial owners of more than 5% of capital stock.
• On May 27, 2025, the company entered into a promissory note with Ching-Hang Shen, an existing 5%+ stockholder, for a $1,000,000 loan (Investor Loan) at 1% interest per month, to be repaid shortly after the IPO.
• In connection with the Investor Loan, the company expects to issue 7,508 shares of common stock to Mr. Shen.
• The company entered into an amended and restated investor rights agreement on November 21, 2019, with preferred stockholders, including 5%+ holders and entities affiliated with directors, providing registration rights and a right of first refusal for future securities (terminates upon IPO completion).
• An amended and restated voting agreement (November 21, 2019) with certain common and preferred stockholders, including directors and executive officers, will terminate upon IPO completion.
• An amended and restated right of first refusal and co-sale agreement (November 21, 2019) with certain common and preferred stockholders, including directors and executive officers, will terminate upon IPO completion.
• Material transactions with related parties for Q1 2025 were limited to $361,000 in R&D expenses for non-recurring engineering services with a vendor holding an insignificant percentage of capital stock.
• Material transactions with related parties for 2024 and 2023 were limited to R&D expenses of $320,000 and $1,000,000 respectively, with a vendor holding an insignificant percentage of capital stock.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience significant dilution from the IPO. Future capital raises could further dilute ownership. The lack of dividends means returns depend on stock price appreciation. The 'going concern' warning poses a risk to investment value. Lock-up agreements restrict sales for 6 months post-IPO for most existing holders.
• **Employees:** The company plans to increase headcount to support growth. The 2025 Equity Incentive Plan aims to attract, motivate, retain, and reward employees through equity awards. However, the company's financial instability could impact job security or future compensation.
• **Customers (Gastroenterologists, Clinics, Hospitals):** Will benefit from continued product innovation, including AI-assisted reading and new products like CapsoCam Colon. Telemedicine supervision and pediatric indications for CapsoCam Plus offer increased flexibility and patient access. However, cost-containment efforts by GPOs and potential reimbursement challenges could affect product affordability and adoption.
• **Suppliers:** The company relies heavily on single-source suppliers in Asia, creating dependency. Geopolitical and trade risks in Asia could disrupt supply chains, impacting the company's ability to meet demand and fulfill orders.
• **Creditors:** The 'going concern' warning and history of losses indicate increased risk for creditors. The $1 million loan from an existing investor highlights immediate liquidity needs.

Next Steps

• Complete the initial public offering of 5,250,000 shares of common stock.
• Repay the $1 million loan from Ching-Hang Shen using IPO proceeds.
• Continue research and development activities for CapsoCam Plus AI, CapsoCam Colon, esophageal varices, and pancreatic neoplasia studies.
• Target FDA 510(k) and EU submissions for CapsoCam Plus with AI assisted reading technology in H2 2025.
• Target FDA and EU clearance of updated CapsoCam Plus with AI by end of 2025.
• Develop a capsule delivery device for CapsoCam Plus, with availability expected in 2025.
• Plan tentative FDA 510(k) submission for a patency capsule by Q3 2025.
• Continue the second arm of the CapsoCam Colon pivotal study (approximately 300 patients at up to 11 U.S. sites).
• Submit 510(k) application for the second generation of CapsoCam Colon to the FDA in Q1 2026.
• Goal to obtain FDA 510(k) clearance for the first generation CapsoCam Colon in Q1 2026.
• Goal to obtain FDA 510(k) clearance for the second generation CapsoCam Colon by end of Q2 2026.
• Seek FDA clearance of expanded indications for CapsoCam Colon to remove the GI bleeding requirement for patients with major risks for colonoscopy or moderate sedation.
• Commercialize CapsoCam Colon in the U.S. starting in H2 2026.
• Seek EU approval and commercialization for CapsoCam Colon by early 2027.
• Commence feasibility studies of CapsoCam's accuracy in screening esophageal varices in cirrhotic patients in H2 2025.
• Commence feasibility studies of CapsoCam's accuracy in detecting abnormalities indicative of cancerous and precancerous pancreatic neoplasia in H1 2026.
• Continue to improve pathology-detection and classification accuracy of AI algorithms and apply AI to streamline diagnostic and medical-report-generation processes.
• Continue making improvements to CapsoCloud and CapsoView software.
• Evaluate potentially increasing on-hand finished goods inventory to a 6-month supply in 2025.
• Evaluate all suppliers in 2025 to ensure meeting anticipated demand for CapsoCam Colon and mitigate supply chain/geopolitical issues.
• Remediate identified material weaknesses in internal control over financial reporting, including hiring a Corporate Controller and evaluating ERP system upgrade/replacement.
• Maintain listing of common stock on Nasdaq for at least three years.
• Maintain registration of common stock under the Exchange Act for three years.

Key Dates

Recommendation

Keywords

Capsule Endoscopy, Medical Technology, Gastrointestinal Imaging, AI Assisted Reading, Small Bowel Endoscopy, Colon Endoscopy, Polyp Detection, 3D Sensing Technology, FDA Clearance, IPO, Healthcare Diagnostics, Digital Health, Telemedicine, S-1/A Filing, Medtronic Competitor, Corporate Governance, Risk Factors, Financial Performance